Newton Charles W. 4

What Happened

• Charles W. Newton, a director of Coherus Oncology (CHRS), received awards on June 5, 2026: 30,000 restricted stock units (RSUs) and 60,000 derivative awards (reported as an "A" award) at $0.00 per share, total reported value $0. These awards are grants, not open-market purchases or sales, so no cash changed hands.

Key Details

• Transaction date(s) and price(s): 2026-06-05; both awards reported at $0.00 per share.
• Amounts: 30,000 RSUs + 60,000 derivative awards = 90,000 total units granted.
• Vesting / exercisability (footnotes):
  • F1 (RSUs): 30,000 RSUs convert to one share per RSU and vest 100% on the one‑year anniversary of June 3, 2026 (i.e., June 3, 2027), subject to continued service.
  • F2 (derivative award): The underlying shares become exercisable/vest 100% on June 3, 2027, subject to continued service.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Filing date / timeliness: Form filed on 2026-06-09 for a 2026-06-05 transaction — this is several days after the trade and may be later than the standard Form 4 deadline (typically within two business days).

Context

• These are forward-looking equity awards with time‑based vesting tied to continued service; they do not represent an immediate purchase or sale of shares and therefore do not by themselves indicate a buy/sell signal.
• The 60,000 derivative awards appear to be option-like or other derivative instruments that will become exercisable/vest on the same vesting date; no cashless exercise or immediate disposition is reported.